Beijing, 100730, China
NCT Number: NCT00478855
Tazocin Intervention Study
1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection. 2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All patients admitted or transferred to the ICU/pulmonary/Infection units
- Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.
Treatment and study plan
Tazocin (Piperacillin/Tazobactem)
DrugPrimary outcomes
-
The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months; post-intervention)
Secondary outcomes
-
The infection rate due to ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months; post-intervention)
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- May 25, 2007
- Registry last updated
- Dec 10, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
NCT07104162
Bacterial Infections, Bacterial Infections and Mycoses
Miami, Florida, United States
View Trial DetailsA Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
NCT00353158
Bacterial Infections, Bacterial Infections and Mycoses
Bethesda, Maryland, United States
View Trial DetailsDose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
NCT02687906
Bacterial Infections, Bacterial Infections and Mycoses
Little Rock, Arkansas, United States
View Trial DetailsStudy to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
NCT05217537
Bacterial Infections, Bacterial Infections and Mycoses
Little Rock, Arkansas, United States
View Trial Details